Bipolar Disorder Therapeutics Market Growth to Remain Stable During the Period 2017 – 2025

Bipolar disorder, also known as manic-depressive disorder, is a mental illness. It is a mental health problem that primarily affects mood. Symptoms of bipolar disorder are extreme irritability or agitation, a period of feeling empty, loss of interest in normal activities, sleep problems, etc. According to Pfizer, Inc., bipolar disorder affects over 5 million people in the U.S. Bipolar episodes are characterized by a drastic change in behavior and mood, and range from joyful and overexcited (manic episodes) to extremely sad and hopeless (depressive state). These disorders have different types of episodes such as manic episodes, hypomanic episodes, depressive episodes, and mixed episodes.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25256

Causes of bipolar disorders include childhood trauma, stressful life events, self-esteem problems, and genetic inheritance. People across the world marked “March 30” as a World Bipolar Day to spread awareness about the disorder and erase the stigma of mental illness. Large number of people suffering from this mental condition resort to drinking to lift their mood. According to the National Institute on Alcohol Abuse and Alcoholism, 27.6% of the people with bipolar disorder become addicted to alcohol, while over 16% engaged in alcohol abuse.

Rise in prevalence of bipolar disorder, high unmet medical needs, technological advancement and government initiatives are the key factors accelerating the growth of the bipolar disorder therapeutics market. According to the National Institute of Mental Health, in 2016, the Johns Hopkins University School of Medicine and the Salk Institute for Biological Studies co-led a US$ 15.4 Mn effort to develop new systems for quickly screening libraries of drugs for potential effectiveness against schizophrenia and bipolar disorder. Increase in investment in research and development and collaboration activities between companies for product development are the other factors likely to propel the bipolar disorder therapeutics market. In 2015, Aequus and Corium entered into product development collaboration focused on CNS diseases such as autistic disorder, bipolar disorder, schizophrenia, and other major depressive disorders. However, stringent regulations acts as a major restraint of the bipolar disorder therapeutics market.

Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=25256

The global bipolar disorder therapeutics market can be segmented based on disease type, drug type, distribution channel, and region. In terms of disease type, the market can be classified into bipolar I, bipolar II, cyclothymia, and others. Based on drug type, the global bipolar disorder therapeutics market can be categorized into mood stabilizers, antipsychotics, antidepressants, and others. In terms of distribution channel, the market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the global bipolar disorder therapeutics market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the global bipolar disorder therapeutics market due to new product innovation, increased awareness among people about bipolar disease, and rise in prevalence of bipolar disorders. According to the National Institutes of Health, in the U.S., 48.8% people with bipolar disorder are receiving treatment. Europe is the second largest market for bipolar disorder therapeutics. The market in Asia Pacific is expected to expand at a higher growth rate due to increase in investment in research & development, growing awareness among people, rise in investment by pharmaceutical companies, and availability of skilled manpower for product manufacturing. According to Graphiq, Inc., per year 100,000 people lost their life from bipolar disorder in India has increased by 14.3% since 1990, an average of 0.6% a year.

Request for the TOC of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=25256

Major players operating in the global bipolar disorder therapeutics market include Eli Lilly and Company, AstraZeneca plc, Pfizer, Inc., Janssen Pharmaceuticals, Otsuka America Pharmaceutical, Inc., and Allergan plc.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *